Kidney Disease & Nephrology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

This large Phase III trial is testing an oral drug called HRS-7535 in people with chronic kidney disease. The goal is to find out if this new medication can better protect the kidneys and lower heart risks compared to current treatments. The study is enrolling nearly 4,000 participants in China, which could speed up the availability of a new option for kidney disease care if results are positive.

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

This international Phase III trial is testing a combination pill for adults with moderate to severe chronic kidney disease. The medication combines balcinrenone and dapagliflozin to see if it can slow down kidney damage and reduce heart problems in people with serious kidney decline. With plans to enroll 2,800 patients, this study could offer a new treatment for those in later stages of kidney disease.

Renal Mechanism of SGLT2 Inhibition

Conducted in the United States, this Phase 2 study is exploring how canagliflozin, a drug used in type 2 diabetes, protects the kidneys in patients with diabetic kidney disease. By understanding the kidney effects better, researchers hope to improve treatments that maintain kidney function and prevent complications. The study involves detailed kidney testing and is currently active but not recruiting new participants.

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

This Phase 2 trial is testing semaglutide in people with type 1 diabetes who have diabetic kidney disease. The goal is to evaluate whether semaglutide can reduce kidney damage and help improve how well the kidneys work. Recruiting in the US and Canada, this study offers hope for a new treatment approach for a group of patients with limited options.

Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury

This Phase 2 trial is investigating whether the drug R2R01 can prevent acute kidney injury in patients undergoing high-risk heart surgery. Acute kidney injury after surgery is a serious problem, and this study may lead to ways to protect the kidneys during these procedures. The trial is recruiting adults in Italy who have risk factors like chronic kidney disease or diabetes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.